nccn guidelines and fda approvals for treating ovarian cancer
Published 4 years ago • 146 plays • Length 4:31Download video MP4
Download video MP3
Similar videos
-
6:10
ovarian cancer: updates to nccn guidelines
-
9:08
fda approvals in cervical cancer, ovarian cancer, and cll, and more
-
2:40
nccn animation for patients: maintenance therapy after initial treatment for ovarian cancer
-
7:19
fda approval in hcc, priority reviews in tnbc and ovarian cancer, snda in itp, and more
-
2:19
dr. arend on fda approval of frontline bevacizumab in ovarian cancer
-
7:39
fda approvals in all, ovarian cancer, priority review in ctcl, and snda submitted in rcc
-
26:02
updates in ovarian cancer: frontline maintenance
-
5:37
maintenance therapy: nccn guidelines, paola-1 trial
-
1:47
new approaches to the treatment of ovarian cancer video
-
1:59
currently accepted regimens: nccn guidelines
-
23:15
is it time to change upfront chemotherapy for ovarian cancer?
-
8:51
fda approvals in nets, breast cancer, aml, a biosimilar, and more
-
3:30
nccn oral antiemetic guidelines
-
10:11
priority review designation in cervical cancer, odac recommendation in all, and more
-
7:44
frontline treatments in ovarian cancer
-
8:26
the impact of paola-1 on frontline treatment of ovarian cancer
-
11:32
fda approvals in breast cancer and nsclc, nda accepted in hcc, and more
-
5:56
approaching platinum-sensitive recurrent ovarian cancer
-
29:19
recommended follow-up guidelines for ovarian cancer